Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial.

ABSTRACT:

Background

Uterine leiomyomas are the most common neoplasm affecting women and frequently cause heavy menstrual bleeding and pain. Gonadotropin-releasing hormone (GnRH) receptor antagonists provide fast symptom relief and show promise as a medical (non-surgical) treatment option and as a presurgical treatment to reduce leiomyoma size. The aim of this study was to evaluate the efficacy and safety of three dose levels of oral relugolix, a small molecule GnRH receptor antagonist, in Japanese women with uterine leiomyomas and heavy menstrual bleeding.

Methods

This phase 2, multicenter, double-blind, parallel-group study was conducted at 36 sites in Japan in women with uterine leiomyomas and heavy menstrual bleeding, defined as a pictorial blood loss assessment chart (PBAC) score

SUBMITTER: Hoshiai H 

PROVIDER: S-EPMC8555132 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature